BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients

A single-center retrospective analysis examined outcomes in 89 patients with newly diagnosed Waldenstroms Macroglobulinemia who received the BR regimen (bendamustine and rituximab). The study assessed overall survival, progression-free survival, time to next treatment, and event-free survival as primary outcomes, alongside clinical characteristics, treatment patterns, and response rates as secondary outcomes.

Median overall survival was 8.49 years, and median progression-free survival was 2.15 years. The median time to next treatment was 3.88 years. Overall response rates were reported at 87.8%. Among the outcomes measured, the BR regimen demonstrated the highest event-free survival.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported in the available evidence. The study was conducted in a real-world setting without a specified comparator arm or defined follow-up duration. No statistical significance values or confidence intervals were provided for the reported results.

Limitations of this analysis include its retrospective nature, single-center design, and small sample size of 89 patients. The absence of a control group and missing safety data restricts the ability to draw definitive conclusions regarding comparative efficacy or the risk-benefit profile of the BR regimen in this population.